Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow APLM by emailGet an email when APLM pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about APLM, unsubscribe in one click. Privacy
📣 What APLM Says Is Next
first half of 2027 · ““Based on guidance from the U.S. Food and Drug Administration (FDA), we anticipate submitting an Investigational New Drug Application for accelerated approval of vebreltinib for second-line treatment for non-small cell lung cancer (NSCLC) patients with c-MET amplification in the first half of 2027.” Pipeline Update”
Company press release, Apr 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full APLM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APLM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.